EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) with EGFR activating mutations - real world data

被引：0
|
作者：
Dulloo, Sean [1 ]
Almusarhed, Manar [1 ]
Chen, Ryan [2 ]
Akala, Oyeyemi [1 ]
Varadhan, Balaji [1 ]
Chauhan, Meera [1 ]
Ahmed, Samreen [1 ]
机构：
[1] Univ Hosp Leicester NHS Trust, Leicester Royal Infirm, Leicester, Leics, England
[2] Univ Leicester, Leicester, Leics, England
来源：
LUNG CANCER | 2021年 / 156卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
96
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [41] A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs)
    Enrico, D. H.
    Lacroix, L.
    Rouleau, E.
    Scoazec, J-Y
    Loriot, Y.
    Tselikas, L.
    Jovelet, C.
    Planchard, D.
    Gazzah, A.
    Mezquita, L.
    Ngo, M.
    Michiels, S.
    Maillard, A.
    Massard, C.
    Facchinetti, F.
    Soria, J-C
    Andre, F.
    Vassal, G.
    Friboulet, L.
    Besse, B.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [42] Durable response to EGFR tyrosine kinase inhibitors in a patient with non-small cell lung cancer harboring an EGFR kinase domain duplication
    Hirokawa, Esuteru
    Watanabe, Satomi
    Sakai, Kazuko
    Takeda, Masayuki
    Sato, Chihiro
    Takahama, Takayuki
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    [J]. THORACIC CANCER, 2021, 12 (16) : 2283 - 2287
  • [43] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib
    Masood, Ashiq
    Kancha, Rama Krishna
    Subramanian, Janakiraman
    [J]. SEMINARS IN ONCOLOGY, 2019, 46 (03) : 271 - 283
  • [44] EGFR TYROSINE KINASE INHIBITOR USED IN NON-SMALL CELL LUNG CANCER
    Joshi, Pooja
    Singh, Anita
    Bisht, Dheeraj
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (03): : 1033 - 1041
  • [45] Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients
    Chen, K.
    Yu, X.
    Wang, H.
    Huang, Z.
    Xu, Y.
    Gong, L.
    Fan, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2131 - S2131
  • [46] Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach
    Jassem, Jacek
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S387 - S390
  • [47] EGFR haplotypes confer risk for tyrosine kinase domain mutations in non-small cell lung cancer
    Liu, Wanqing
    He, Lijun
    Krishnaswamy, Soundararajan
    Kanteti, Rajani
    Wang, Yi-Ching
    Salgia, Ravi
    Ratain, Mark
    [J]. CANCER RESEARCH, 2009, 69
  • [48] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Fukihara, Jun
    Watanabe, Naohiro
    Taniguchi, Hiroyuki
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Matsuda, Toshiaki
    Yokoyama, Toshiki
    Hasegawa, Yoshinori
    [J]. ONCOLOGY, 2014, 86 (02) : 86 - 93
  • [49] Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
    Maevskaya, J.
    Laktionov, K.
    Yudin, D.
    Vladimirova, L.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1402 - S1402
  • [50] EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Otsuka, K.
    Hata, A.
    Kato, R.
    Takeshita, J.
    Okuda, C.
    Kaji, R.
    Masago, K.
    Fujita, S.
    Katakami, N.
    [J]. ANNALS OF ONCOLOGY, 2014, 25
12345